Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

Mabthera(R) (Rituximab) Available On NHS For UK's Most Common Leukaemia
The National Institute for Health and Clinical Excellence (NICE) today issued its recommendation for the use of MabThera® (rituximab) in the UK"s most common form of leukaemia, chronic lymphocytic leukaemia (CLL).1,2,3 NICE"s final guidance recommends rituximab in combination with fludarabine and cyclophosphamide (FC) chemotherapy as an option for previously untreated patients with CLL.4 The addition of rituximab to FC chemotherapy has been proven to halt progression of the disease by 10.5 months longer than chemotherapy alone, and more than doubles the number of CLL patients achieving complete remission, compared to chemotherapy.5,6 More than 20,000 people in the UK are living with CLL and there are an estimated 3,700 new cases every year.7,8 Professor John Gribben, Consultant Haematologist and Medical Oncologist, Barts and The London NHS Trust, commented:
pharmacy online
Electronic Medical Record Technology Uptake Faces Challenges
HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that while health systems and physician groups in the Phoenix market seem to be ahead of the curve in adopting electronic medical records (EMR), there is a high rate of "deinstallation" wherein physician groups cancel their EMR contracts as a result of training, functionality or affordability issues. According to the recent Phoenix Market Overview, this trend is especially prevalent among smaller physician groups and points to the need for a simplified, affordable solution.
News of the day
GlaxoSmithKline And Genmab Announce Top-line Results For Ofatumumab In Rheumatoid Arthritis
GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced preliminary top-line results from a Phase III study of ofatumumab administered intravenously for the treatment of rheumatoid arthritis (RA) in patients who had an inadequate response to methotrexate. The study met the primary endpoint, ACR20 at 24 weeks, which indicates a 20 percent or greater improvement in the number of swollen and tender joints, as well as improvements in other disease-activity measures.
Diagnostics

Food Manufacturers Must Step Up To The Plate And Reduce Salt Levels, Says Heart Charity

In response to Food Standards Agency"s new guidelines on voluntary salt reduction targets, Alex Callaghan, Policy Officer at the British Heart Foundation (BHF), said: "While it is fantastic the nation is reducing its salt intake, we are still moving at a snail"s pace. At the current rate of reduction, it would take us 15 years to reach the 6g per day target, putting another generation at risk of high blood pressure and heart disease. "Food manufacturers must step up to the plate and do all that they can to reduce the vast amounts of salt we consume in everyday products, such as cereals and ready meals. "As well as reducing salt, they can also help busy shoppers in supermarkets to make healthier choices by using a food labelling system that incorporates traffic lights, GDAs, and the words high, medium or low." The British Heart Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009